pediatric patients

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

August 19, 2026

Teva Pharmaceutical Industries Ltd Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA…

MMedication

FDA Greenlights Glenmark's Ryaltris Allergy Spray for Children Ages 6-12, ETPharma

July 22, 2026

Mumbai: Glenmark Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved the expanded use of…

MMedication

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

June 27, 2026

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or…

HHealthcare

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

June 11, 2026

Approval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older…

MMedication

Galderma Group (SWX:GALD) Valuation Check After Recent Share Price Weakness And R&D Driven Growth Hopes

May 2, 2026

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

FDA Greenlights Glenmark’s Ryaltris Allergy Spray for Children Ages 6-12, ETPharma

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Novo Nordisk Expands GLP-1 Reach With Oral Ozempic And Pediatric Push